Last reviewed · How we verify
Secondary malignant neoplasm of colon
Approved treatments
- Avastin · Washington University School of Medicine
- Bevacizumab · Roche
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR. - Avastin · Roche
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors. - vectibix · Centre Jean Perrin
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Secondary malignant neoplasm of colon patent landscape — cliff calendar, originator estates, attackable patents
- Secondary malignant neoplasm of colon treatment landscape brief
- Secondary malignant neoplasm of colon treatment updates RSS
Frequently asked questions about Secondary malignant neoplasm of colon
What drugs treat Secondary malignant neoplasm of colon?
Tracked treatments include Avastin, Bevacizumab, vectibix.
What is the treatment for Secondary malignant neoplasm of colon?
Standard treatment for Secondary malignant neoplasm of colon includes Avastin, Bevacizumab, vectibix. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Secondary malignant neoplasm of colon patent cliff · Secondary malignant neoplasm of colon CI report
- Treatment: Avastin · Washington University School of Medicine
- Treatment: Bevacizumab · Roche
- Treatment: Avastin · Roche
- Treatment: vectibix · Centre Jean Perrin
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing